Insider Selling: Advisory Board CEO Unloads 10,000 Shares of Stock (ABCO)
Advisory Board (NASDAQ:ABCO) CEO Robert W. Musslewhite sold 10,000 shares of the company’s stock on the open market in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $63.97, for a total value of $639,700.00. Following the completion of the transaction, the chief executive officer now directly owns 29,059 shares of the company’s stock, valued at approximately $1,858,904. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of Advisory Board (NASDAQ:ABCO) traded down 0.63% during mid-day trading on Monday, hitting $64.32. 295,495 shares of the company’s stock traded hands. Advisory Board has a 1-year low of $44.20 and a 1-year high of $70.55. The stock has a 50-day moving average of $61.77 and a 200-day moving average of $61.60. The company has a market cap of $2.325 billion and a price-to-earnings ratio of 109.71.
Advisory Board (NASDAQ:ABCO) last released its earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by $0.03. The company had revenue of $131.00 million for the quarter, compared to the consensus estimate of $132.58 million. During the same quarter in the previous year, the company posted $0.28 earnings per share. The company’s revenue for the quarter was up 12.7% on a year-over-year basis. Analysts expect that Advisory Board will post $1.18 EPS for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Ned Davis Research upgraded shares of Advisory Board from a “sell” rating to a “neutral” rating in a research note on Monday. Analysts at Zacks downgraded shares of Advisory Board from a “neutral” rating to an “underperform” rating in a research note on Thursday, February 13th. They now have a $57.90 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $63.65.
The Advisory Board Company provides best practices research and analysis, software tools, and management and advisory services to the health care and education industries.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.